Corvus Pharmaceuticals, Inc. Research and Development Expense
Corvus Pharmaceuticals, Inc. (CRVS) reported Research and Development Expense of $15.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $15.96M, a 102.77% increase year-over-year.
- Corvus Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $11.18M, a 49.94% increase year-over-year.
- Corvus Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $9.94M, a 66.37% increase year-over-year.
- Corvus Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $8.45M, a 61.89% increase year-over-year.
- Corvus Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $33.72M, a 73.94% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $19.39M, a 17.30% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $16.53M, a 32.46% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $24.47M, a 15.96% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 11 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $15.96M 10-Q · filed 2026-08-06 | $27.14M 10-Q · filed 2026-08-06 | $37.08M derived: sum of 3 quarters · filed 2026-08-06 | $45.53M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $11.18M 10-Q · filed 2026-05-07 | $21.11M derived: sum of 2 quarters · filed 2026-05-07 | $29.57M derived: sum of 3 quarters · filed 2026-05-07 | $37.44M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $9.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $18.39M derived: sum of 2 quarters · filed 2026-03-12 | $26.27M derived: sum of 3 quarters · filed 2026-08-06 | $33.72M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $8.45M 10-Q · filed 2025-11-04 | $16.33M derived: sum of 2 quarters · filed 2026-08-06 | $23.78M 10-Q · filed 2025-11-04 | $29.75M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $7.87M 10-Q · filed 2026-08-06 | $15.33M 10-Q · filed 2026-08-06 | $21.30M derived: sum of 3 quarters · filed 2026-08-06 | $26.52M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $7.45M 10-Q · filed 2026-05-07 | $13.43M derived: sum of 2 quarters · filed 2026-05-07 | $18.65M derived: sum of 3 quarters · filed 2026-05-07 | $22.76M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $11.20M derived: sum of 2 quarters · filed 2026-03-12 | $15.31M derived: sum of 3 quarters · filed 2026-03-12 | $19.39M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $5.22M 10-Q · filed 2025-11-04 | $9.34M derived: sum of 2 quarters · filed 2025-11-04 | $13.41M 10-Q · filed 2025-11-04 | $17.41M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | $4.11M 10-Q · filed 2025-08-07 | $8.19M 10-Q · filed 2025-08-07 | $12.19M derived: sum of 3 quarters · filed 2026-03-12 | $16.15M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | $4.08M 10-Q · filed 2025-05-08 | $8.07M derived: sum of 2 quarters · filed 2026-03-12 | $12.04M derived: sum of 3 quarters · filed 2026-03-12 | $16.01M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $7.96M derived: sum of 2 quarters · filed 2026-03-12 | $11.93M derived: sum of 3 quarters · filed 2026-03-12 | $16.53M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $3.96M 10-Q · filed 2024-11-12 | $7.93M derived: sum of 2 quarters · filed 2024-11-12 | $12.53M 10-Q · filed 2024-11-12 | $16.61M derived: sum of 4 quarters · filed 2025-03-25 | |
| 2023-06-30 | $3.97M 10-Q · filed 2024-08-06 | $8.56M 10-Q · filed 2024-08-06 | $12.64M derived: sum of 3 quarters · filed 2025-03-25 | $23.01M derived: sum of 4 quarters · filed 2025-03-25 | |
| 2023-03-31 | $4.59M 10-Q · filed 2024-05-07 | $8.67M derived: sum of 2 quarters · filed 2025-03-25 | $19.04M derived: sum of 3 quarters · filed 2025-03-25 | $23.96M derived: sum of 4 quarters · filed 2025-03-25 | |
| 2022-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $14.45M derived: sum of 2 quarters · filed 2025-03-25 | $19.37M derived: sum of 3 quarters · filed 2025-03-25 | $24.47M 10-K · filed 2025-03-25 | |
| 2022-09-30 | $10.37M 10-Q · filed 2023-11-07 | $15.29M derived: sum of 2 quarters · filed 2023-11-07 | $20.39M 10-Q · filed 2023-11-07 | $25.18M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | $4.92M 10-Q · filed 2023-08-08 | $10.02M 10-Q · filed 2023-08-08 | $14.81M derived: sum of 3 quarters · filed 2024-03-19 | $21.80M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | $5.10M 10-Q · filed 2023-05-08 | $9.89M derived: sum of 2 quarters · filed 2024-03-19 | $16.88M derived: sum of 3 quarters · filed 2024-03-19 | $25.98M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $11.78M derived: sum of 2 quarters · filed 2024-03-19 | $20.89M derived: sum of 3 quarters · filed 2024-03-19 | $29.11M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $6.99M 10-Q · filed 2022-11-03 | $16.10M derived: sum of 2 quarters · filed 2022-11-03 | $24.33M 10-Q · filed 2022-11-03 | $31.52M derived: sum of 4 quarters · filed 2023-03-28 | |
| 2021-06-30 | $9.11M 10-Q · filed 2022-08-08 | $17.34M 10-Q · filed 2022-08-08 | $24.53M derived: sum of 3 quarters · filed 2023-03-28 | $31.15M derived: sum of 4 quarters · filed 2023-03-28 | |
| 2021-03-31 | $8.23M 10-Q · filed 2022-05-05 | $15.42M derived: sum of 2 quarters · filed 2023-03-28 | $22.04M derived: sum of 3 quarters · filed 2023-03-28 | $29.90M derived: sum of 4 quarters · filed 2023-03-28 | |
| 2020-12-31 | $7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $13.81M derived: sum of 2 quarters · filed 2023-03-28 | $21.67M derived: sum of 3 quarters · filed 2023-03-28 | $31.83M 10-K · filed 2023-03-28 | |
| 2020-09-30 | $6.62M 10-Q · filed 2021-11-01 | $14.48M derived: sum of 2 quarters · filed 2021-11-01 | $24.64M 10-Q · filed 2021-11-01 | $33.56M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | $7.86M 10-Q · filed 2021-08-02 | $18.02M 10-Q · filed 2021-08-02 | $26.94M derived: sum of 3 quarters · filed 2022-03-10 | $35.94M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | $10.16M 10-Q · filed 2021-04-29 | $19.08M derived: sum of 2 quarters · filed 2022-03-10 | $28.08M derived: sum of 3 quarters · filed 2022-03-10 | $38.72M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | $8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $17.92M derived: sum of 2 quarters · filed 2022-03-10 | $28.56M derived: sum of 3 quarters · filed 2022-03-10 | $37.98M 10-K · filed 2022-03-10 | |
| 2019-09-30 | $9.00M 10-Q · filed 2020-10-29 | $19.64M derived: sum of 2 quarters · filed 2020-10-29 | $29.05M 10-Q · filed 2020-10-29 | $37.45M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-06-30 | $10.64M 10-Q · filed 2020-07-30 | $20.06M 10-Q · filed 2020-07-30 | $28.45M derived: sum of 3 quarters · filed 2021-03-25 | $36.83M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-03-31 | $9.42M 10-Q · filed 2020-04-30 | $17.81M derived: sum of 2 quarters · filed 2021-03-25 | $26.19M derived: sum of 3 quarters · filed 2021-03-25 | $35.90M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2018-12-31 | $8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $16.77M derived: sum of 2 quarters · filed 2021-03-25 | $26.48M derived: sum of 3 quarters · filed 2021-03-25 | $38.59M 10-K · filed 2021-03-25 | |
| 2018-09-30 | $8.37M 10-Q · filed 2019-10-29 | $18.09M derived: sum of 2 quarters · filed 2019-10-29 | $30.19M 10-Q · filed 2019-10-29 | $39.88M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2018-06-30 | $9.71M 10-Q · filed 2019-08-01 | $21.82M 10-Q · filed 2019-08-01 | $31.51M derived: sum of 3 quarters · filed 2020-03-09 | $42.24M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2018-03-31 | $12.10M 10-Q · filed 2019-05-09 | $21.79M derived: sum of 2 quarters · filed 2020-03-09 | $32.52M derived: sum of 3 quarters · filed 2020-03-09 | $44.91M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2017-12-31 | $9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $20.42M derived: sum of 2 quarters · filed 2020-03-09 | $32.81M derived: sum of 3 quarters · filed 2020-03-09 | $46.30M 10-K · filed 2020-03-09 | |
| 2017-09-30 | $10.73M 10-Q · filed 2018-11-01 | $23.12M derived: sum of 2 quarters · filed 2018-11-01 | $36.62M 10-Q · filed 2018-11-01 | $45.75M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-06-30 | $12.39M 10-Q · filed 2018-08-02 | $25.88M 10-Q · filed 2018-08-02 | $35.02M derived: sum of 3 quarters · filed 2019-03-07 | $42.72M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-03-31 | $13.50M 10-Q · filed 2018-05-03 | $22.63M derived: sum of 2 quarters · filed 2019-03-07 | $30.34M derived: sum of 3 quarters · filed 2019-03-07 | $37.45M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2016-12-31 | $9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $16.84M derived: sum of 2 quarters · filed 2019-03-07 | $23.96M derived: sum of 3 quarters · filed 2019-03-07 | $29.36M 10-K · filed 2019-03-07 | |
| 2016-09-30 | $7.71M 10-Q · filed 2017-11-02 | $14.83M derived: sum of 2 quarters · filed 2017-11-02 | $20.22M 10-Q · filed 2017-11-02 | $25.13M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $7.12M 10-Q · filed 2017-08-03 | $12.52M 10-Q · filed 2017-08-03 | $17.43M derived: sum of 3 quarters · filed 2018-03-01 | $19.94M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $5.40M 10-Q · filed 2017-05-04 | $10.31M derived: sum of 2 quarters · filed 2018-03-01 | $12.82M derived: sum of 3 quarters · filed 2018-03-01 | $14.82M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $7.42M derived: sum of 2 quarters · filed 2018-03-01 | $9.43M derived: sum of 3 quarters · filed 2018-03-01 | $11.35M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $2.51M 10-Q · filed 2016-11-03 | $4.52M derived: sum of 2 quarters · filed 2016-11-03 | $6.44M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $2.00M 10-Q · filed 2016-08-04 | $3.93M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $1.92M 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | $38.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |